Management of Hypercalcemia with Normal PTH Levels

Diagnostic Approach

Review all medications, particularly calcium supplements, as they can contribute to hypercalcemia, according to Praxis Medical Insights 1
Avoid vitamin D therapy and calcium supplementation as these could worsen hypercalcemia, as recommended by Praxis Medical Insights 1

Monitor serum calcium and ionized calcium levels every 1-2 weeks until stable, as suggested by Praxis Medical Insights 1

In patients with chronic kidney disease, maintain serum phosphate concentrations in the normal range, as recommended by the National Kidney Foundation 2, 3
For patients with hypercalcemia and calciphylaxis with elevated PTH (>500 pg/mL), consider parathyroidectomy, according to the American Journal of Kidney Diseases 4
Consider parathyroidectomy for tertiary hyperparathyroidism (persistent hypercalcemic hyperparathyroidism) despite optimized medical therapy, as suggested by the National Institute of Diabetes and Digestive and Kidney Diseases, and reported in Nature Reviews Nephrology 5

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest that patients with stage 2 chronic kidney disease, like the one presented with an eGFR of 68 mL/min/1.73m², require careful management of mineral bone disorders, although this is not the primary cause of hypercalcemia in this case 6, 7
The National Kidney Foundation recommends maintaining serum phosphate concentrations in the normal range for patients with chronic kidney disease, and avoiding calcium-based phosphate binders if phosphate becomes elevated, as suggested by the Kidney International guidelines 6, 7
For patients with chronic kidney disease who may require dialysis, the Kidney International guidelines suggest considering a dialysate calcium concentration between 1.25 and 1.50 mmol/L 6, 7

Measure PTH-related protein (PTHrP) to evaluate for malignancy-associated hypercalcemia, which is characterized by suppressed PTH and elevated PTHrP, in patients with hypercalcemia and normal PTH levels 8
Obtain 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels to assess for vitamin D intoxication or granulomatous disease in patients with hypercalcemia and normal PTH levels 8

Initiate aggressive IV crystalloid hydration with normal saline to restore intravascular volume and promote calciuresis in patients with moderate to severe hypercalcemia (Total Calcium ≥12 mg/dL) 8
Administer loop diuretics (furosemide) only after adequate volume repletion to enhance calcium excretion in patients with moderate to severe hypercalcemia (Total Calcium ≥12 mg/dL) 8
Give IV bisphosphonates (zoledronic acid or pamidronate) as primary therapy for PTH-independent hypercalcemia in patients with moderate to severe hypercalcemia (Total Calcium ≥12 mg/dL) 8
Consider calcitonin as a temporizing measure for rapid calcium reduction while awaiting bisphosphonate effect in patients with moderate to severe hypercalcemia (Total Calcium ≥12 mg/dL) 8
Initiate hypertonic 3% saline IV in addition to aggressive hydration for acute symptomatic severe hypercalcemia (Total Calcium ≥14 mg/dL or Ionized Calcium ≥10 mg/dL) 8

PTHrP-mediated hypercalcemia is characterized by suppressed PTH (<20 pg/mL) and low or normal calcitriol levels, with a median survival of approximately 1 month after discovery in lung cancer patients, emphasizing the need for aggressive symptom management 8
Avoid calcium-based phosphate binders in CKD patients with hypercalcemia, as recommended by the National Kidney Foundation 9

Normal PTH in the setting of hypercalcemia is inappropriate, indicating PTH-independent hypercalcemia, which requires different management than primary hyperparathyroidism, according to the American Thoracic Society 10
Malignancy is the most common cause of hypercalcemia in hospitalized patients, with a median survival of approximately 1 month after discovery in lung cancer patients, emphasizing the need for aggressive symptom management, as recommended by the American College of Chest Physicians 10
Elevated PTHrP with suppressed PTH indicates malignancy-associated hypercalcemia, while normal PTH with elevated PTHrP suggests paraneoplastic syndrome, as stated by the National Comprehensive Cancer Network 10

For severe symptomatic hypercalcemia, initiate hypertonic 3% saline IV in addition to aggressive hydration for acute symptomatic cases with mental status changes, bradycardia, or hypotension, as recommended by the American Heart Association 10
Treat underlying malignancy urgently with chemotherapy or radiation as this is the definitive treatment for malignancy-associated hypercalcemia, according to the National Cancer Institute 10

If PTHrP is elevated, treat underlying malignancy urgently with chemotherapy or radiation, and use IV bisphosphonates as primary therapy while treating malignancy, as recommended by the European Society for Medical Oncology 10
If 1,25-dihydroxyvitamin D is elevated, glucocorticoids are the primary treatment when hypercalcemia is due to excessive intestinal calcium absorption from vitamin D, as stated by the Endocrine Society 10